Beth Hoffman

Bio:

At Origami Therapeutics, Dr. Hoffman has created a new approach to discovering curative medicines for neurodegenerative diseases, leveraging her experience from CNS drug discovery and from discovering transformational therapies for Cystic Fibrosis (CF). Prior to Origami, she was a R&D Executive at Vertex Pharmaceuticals, Amgen and Eli Lilly & Co. She made major contributions to >30 programs that advanced to clinical trials, to four marketed drugs for CF (Kalydeco, Orkambi, Symdeco, Trikafta) that created a paradigm shift in CF treatment by targeting the underlying cause of disease by modulating protein folding and to label expansions for Kalydeco, enlarging its market and increasing sales by >$1 billion. She led the research generating a novel non-opioid pain therapeutic, now launched as Journavx. Dr. Hoffman received her A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from the Johns Hopkins University. She was awarded the Prize of the Anna Monika Foundation for depression research. Dr. Hoffman serves on the Board of Directors for Biofrontera Inc. (NASDAQ: BFRI), the SAB for the Tau Consortium of the Rainwater Charitable Foundation and the National Board of Trustees for the Huntington’s Disease Society of America (HDSA).